LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
44.20
+0.13 (0.29%)
May 9, 2025, 11:28 AM - Market open
LivaNova Revenue
LivaNova had revenue of $316.86M in the quarter ending March 31, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to $1.28B, up 7.62% year-over-year. In the year 2024, LivaNova had annual revenue of $1.25B with 8.66% growth.
Revenue (ttm)
$1.28B
Revenue Growth
+7.62%
P/S Ratio
1.88
Revenue / Employee
$439,786
Employees
2,900
Market Cap
2.41B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.25B | 99.89M | 8.66% |
Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LIVN News
- 2 days ago - LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance - Business Wire
- 2 days ago - LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy - Business Wire
- 6 weeks ago - LivaNova to Announce First-Quarter 2025 Results - Business Wire
- 2 months ago - LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance - Business Wire
- 2 months ago - LivaNova to Present at the Barclays Global Healthcare Conference - Business Wire
- 3 months ago - LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results - Business Wire
- 5 months ago - RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression - Business Wire